Construction and use of Tac promoter-based plasmid expression vectors
By modifying the Shine-Dalgarno sequence in pGEX plasmid vectors, the expression of HPV L1 antigen protein is enhanced, addressing safety and cost issues in existing fusion protein technologies, enabling efficient and large-scale production of HPV vaccines.
Patent Information
- Application Number
- JP2025568960
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-02-15
- Filing Date
- 2024-02-06
- Publication Date
- 2026-02-16
AI Technical Summary
Current fusion protein expression vectors, such as pGEX, face challenges with linker sequence length affecting protein folding and stability, immunogenicity, and the use of expensive enzymes for cleavage, which complicates large-scale production of HPV L1 protein and introduces safety risks.
Modification of the Shine-Dalgarno (SD) sequence in pGEX plasmid vectors to construct non-fusion expression vectors, enabling efficient and soluble expression of HPV L1 antigen protein, eliminating the need for expensive enzymes and tag proteins, and achieving high yields.
The modified SD sequence expression vectors achieve 5-10 times higher expression levels of HPV L1 antigen protein, facilitating low-cost, large-scale production of cervical cancer vaccines and virus-like particles with improved safety and purity.